Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice.
Semaglutide shows significant kidney benefits in non-diabetic obese patients with heart disease
A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight